First phase III trial of Zactima in NSCLC completes enrollment
First phase III trial of Zactima in NSCLC completes enrollment
WILMINGTON, Delaware-AstraZeneca has completed enrollment of patients in ZEST (Zactima Efficacy Study vs Tarceva), the first of four phase III lung cancer trials for its once-daily oral anticancer drug Zactima (vandetanib). The agent inhibits VEGFR, EGFR, and RET tyrosine kinases. ZEST is comparing vandetanib against erlotinib (Tarceva) in more than 1,150 patients with locally advanced or metastatic NSCLC after first-line failure. The other studies are ZODIAC (vandetanib + docetaxel [Taxotere] vs docetaxel alone); ZEAL (vandetanib + pemetrexed [Alimta] vs placebo/pemetrexed); and ZEPHYR (vandetanib + best supportive care vs placebo/BSC).
Eric Ko on Combining Radiation Therapy With Immunotherapy to Treat Non–Small-Cell Lung Cancer
September 18th 2018ONCOLOGY spoke with Eric Ko, MD, PhD, who recently published a review article with his colleagues on strategies for combining radiation therapy with immunotherapy for the treatment of non–small-cell lung cancer.
